|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-4.49/-3.14
|
企业价值
953.93M
|
资产负债 |
每股账面净值
6.00
|
现金流量 |
现金流量率
--
|
损益表 |
收益
314.00K
|
每股收益
0.02
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 17:29 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. |